Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL

In treatment-naive patients with chronic lymphocytic leukemia (CLL) who lack TP53 mutations, the fixed-duration combination of venetoclax plus obinutuzumab was associated with longer time to next treatment (TTNT) and better 4-year overall survival (OS) compared with the Bruton's tyrosine kinase (BTK) inhibitor acalabrutinib, although at the cost of higher rates of cytopenias and infectious complications, according to a real-world propensity score-matched analysis published in Cancer Medicine.¹

The findings fill a meaningful gap for the authors, who wrote, “Despite robust phase 3 data supporting each regimen, direct head-to-head comparisons are lacking. Moreover, randomized trials often involve selected populations that may not represent real-world patients, who commonly have more comorbidities, variable adherence, and differing clinical priorities.”

What the Data Revealed

Researchers used the TriNetX global federated health database to identify treatment-naive patients with TP53 wild-type CLL who started first-line therapy after January 1, 2015. After eligibility screening and 1:1 propensity score matching, the analysis included 669 matched pairs receiving either acalabrutinib or venetoclax plus obinutuzumab. Equivalent amounts of patients from each treatment group—20.8% and 20.5%, respectively—were 75 years or older at their index date, or the date of first dose administration. At least 85% of each cohort was White (P = .388).

Patients were followed until death, loss to follow-up, or the April 15, 2025, data cutoff, whichever was earliest. The primary end point was TTNT, and secondary end points were OS and adverse events (AEs). Baseline values for hemoglobin, platelet count, elevated lactate dehydrogenase, and estimated glomerular filtration rate were close to equal.

TTNT strongly favored the venetoclax-based regimen. The median TTNT for acalabrutinib was 47.7 months but was not reached in the venetoclax plus obinutuzumab group. Estimated 4-year TTNT rates were 49.1% vs 63.6% (HR, 1.84; 95% CI, 1.50-2.26; P < .0001). The 4-year OS rate also favored venetoclax plus obinutuzumab: 88.4% vs 81.7% (HR, 1.84; 95% CI, 1.28-2.65; P = .0009), but these data were limited due to the study’s short follow-up (23.4 months for those who received venetoclax and 20.5 months for acalabrutinib) and observational design. Subgroup analyses were consistent across age, sex, race, disease stage, and most comorbidities, with no statistically significant difference among patients with atrial fibrillation, diabetes, or cerebrovascular disease.

Six-year follow-up from the phase 3 CLL14 trial (NCT02242942) showed durable progression-free survival (PFS) and OS with venetoclax plus obinutuzumab, lending clinical trial support to these real-world findings.^2,3

The Tradeoff: Efficacy With a Higher Toxicity Burden

The combination’s clinical advantage came with meaningful AE differences. Compared with acalabrutinib, venetoclax plus obinutuzumab was associated with higher rates of neutropenia (all grades: 54.3% vs 33.3%; grade 3/4: 35.2% vs 20.2%), thrombocytopenia (all grades: 45.9% vs 31.9%), febrile neutropenia (7.1% vs 3.4%), COVID-19 infection (13.1% vs 9.4%), and tumor lysis syndrome (6.3% vs 2.3%).¹ The elevated infection rate is likely tied to obinutuzumab’s suppression of humoral immunity, the authors explained, a pattern consistent with recent reporting on serious infection risk with venetoclax plus obinutuzumab vs zanubrutinib.⁴

Despite the toxicity signals, real-world discontinuation rates for the combination remain low when supported by appropriate monitoring and supportive care. Atrial fibrillation occurred in 9.4% of acalabrutinib-treated patients vs 7.1% in the venetoclax plus obinutuzumab group, a difference that did not reach statistical significance, although cardiovascular risk with BTK inhibitors remains a key clinical consideration.⁵

Why Acalabrutinib Stays the Default in Practice

Before matching, acalabrutinib was prescribed more than 3 times as often (2097 vs 682 patients), reflecting its practical edge: once-daily oral dosing, no intravenous infusions, and lower monitoring intensity. Patients who received venetoclax plus obinutuzumab tended to be younger with a heavier disease burden, a finding also seen in recent real-world data showing that age and genetic risk profile are the primary drivers of frontline regimen selection in CLL.⁶

Real-world treatment durations for acalabrutinib also lag behind trial data, averaging roughly 20.7 months compared with 72 months seen in clinical studies, a gap the authors attribute partly to BTK resistance mutations and early discontinuation due to adverse events or financial barriers.¹

What This Means for Managed Care

The fixed 12-month duration of venetoclax plus obinutuzumab vs acalabrutinib’s continuous use until progression has direct implications for payer formulary strategy. Durable remissions with the combination have the potential to lower long-term drug spend, even though the regimen’s acute toxicity burden, including cytopenias requiring management and higher infection rates, may introduce offsetting costs. The study could not capture adherence, dose intensity, or supportive care use, limiting precision on the cost side. Also, the TriNetX database lacked detailed cytogenetic and molecular information, “precluding subgroup analyses based on established genomic risk factors and potentially influencing treatment outcome comparisons.”

The prospective CLL17 trial is expected to provide randomized head-to-head evidence in this space. Until those results are available, this analysis offers some of the most rigorous real-world data to guide treatment decisions for TP53 wild-type CLL.

References

1. Liao PW, Ko BS, Su YC, Chao WT, Teng CLJ. Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: a real-world propensity score-matched study. Cancer Medicine. 2026;15(6):e72022. doi:10.1002/cam4.72022
2. Kaltwasser J. 6-year data support fixed-duration ven-obi for untreated CLL. AJMC^®. December 10, 2024. Accessed June 16, 2026. https://www.ajmc.com/view/6-year-data-support-fixed-duration-ven-obi-for-untreated-cll
3. Comparison of the treatments of obinutuzumab + venetoclax versus obinutuzumab + chlorambucil in patients with chronic lymphocytic leukemia. ClinicalTrials.gov. Updated November 6, 2025. Accessed June 16, 2026. https://clinicaltrials.gov/study/NCT02242942
4. Rath K. Higher infection risk with venetoclax-obinutuzumab vs zanubrutinib in CLL/SLL. AJMC. July 7, 2025. Accessed June 16, 2026. https://www.ajmc.com/view/higher-infection-risk-with-venetoclax-obinutuzumab-vs-zanubrutinib-in-cll-sll
5. Contributor. Lower risk of cardiovascular events with acalabrutinib vs ibrutinib in CLL in real-world study. AJMC. May 17, 2025. Accessed June 16, 2026. https://www.ajmc.com/view/real-world-findings-confirm-lower-risk-of-cardiovascular-events-with-acalabrutinib-vs-ibrutinib-in-cll
6. Shaw ML. Age and genetics drive real-world CLL treatment choices. AJMC. April 25, 2026. Accessed June 16, 2026. https://www.ajmc.com/view/age-and-genetics-drive-real-world-cll-treatment-choices